Pharmaceutical Compositions Comprising a GPG Oligodeoxynucleotide and Cyclic Di-GMP

Patent metadata

Field	Value
Publication number	US-2016136197-A1
Application number	US-201414898000-A
Country	US
Kind code	A1
Filing date	Jun 13, 2014
Priority date	Jun 14, 2013
Publication date	May 19, 2016
Grant date	—

Abstract

The present invention relates to pharmaceutical compositions comprising an immunostimulatory amount of at least two immunopotentiators, wherein a first immunopotentiator is a non-methylated cytidyl guanosyl oligodeoxynucleotide (CpG ODN) and a second immunopotentiator is 3′,5′-cyclic diguanylic acid (c-di-GMP), and a pharmaceutically acceptable carrier. The invention also relates to the use of such pharmaceutical compositions for the induction of an immune response against tumor-specific antigens. Also the invention relates to their use in in situ tumor-destruction therapy and to such pharmaceutical compositions for use in the treatment of a mammal suffering from cancer.

First claim

1 - 15 . (canceled)

16 . A pharmaceutical composition comprising an immunostimulating amount of at least two immunopotentiators and a pharmaceutically acceptable carrier;
wherein a first immunopotentiator is a non-methylated cytidyl guanosyl oligodeoxynucleotide (CpG ODN); and wherein a second immunopotentiator is 3′,5′-cyclic diguanylic acid (c-di-GMP).

17 . A method of inducing an immune response against tumor-specific antigens in a mammal comprising administering the pharmaceutical composition of claim 16 to the mammal.

18 . A method of performing in situ tumor-destruction therapy in a mammal comprising performing tumor destruction on a tumor in the mammal and administering the pharmaceutical composition of claim 16 to the mammal.

19 . The method of claim 18 wherein the step of performing tumor destruction on the tumor is performed prior to the step of administering the pharmaceutical composition.

20 . The method of claim 19 wherein the step of administrating the pharmaceutical composition follows within 24 hours after the step of tumor destruction.

21 . The method of claim 20 wherein the step of administrating the pharmaceutical composition follows within 12 hours after the step of tumor destruction.

22 . The method of claim 20 wherein the step of administrating the pharmaceutical composition follows within 6 hours after the step of tumor destruction.

23 . A method of performing in situ tumor-destruction therapy in a mammal comprising performing tumor destruction on a tumor in the mammal and administering the pharmaceutical composition of claim 16 peri-operatively to the mammal.

24 . The method of claim 17 , wherein the mode of administering the pharmaceutical composition is intravenous, subcutaneous in the draining area of the neoplastic mass, peri-tumoral or intra-tumoral.

25 . A method of treating a mammal suffering from cancer comprising administering the pharmaceutical composition of claim 16 to the mammal.

26 . A method of treating a mammal suffering from cancer, comprising performing tumor destruction on a tumor in the mammal and administering the pharmaceutical composition of claim 16 peri-operatively to the mammal.

27 . The method of claim 26 wherein the step of performing tumor destruction on the tumor is performed prior to the step of administering the pharmaceutical composition.

28 . The method of claim 26 wherein the step of performing tumor destruction on the tumor is performed after the step of administering the pharmaceutical composition.

Assignees

• Intervet Int Bv
• Intervet Inc

Inventors

• Schrier Carla Christina
• Brok Den Martijn
• Adema Gosse

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/04

  Immunostimulants · CPC title

• A61K31/7088 Primary

  Compounds having three or more nucleosides or nucleotides · CPC title

• A61K31/7084

  Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide · CPC title